Related Experiment Video
Updated: May 17, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
DRAK2 participates in a negative feedback loop to control TGF-β/Smads signaling by binding to type I TGF-β receptor
Kyung-Min Yang1, Wonjoo Kim, Eunjin Bae
1CHA Cancer Institute, CHA University of Medicine and Science, Seoul 135-081, Korea.
Abstract:
TGF-β1 is a multifunctional cytokine that mediates diverse biological processes. However, the mechanisms by which the intracellular signals of TGF-β1 are terminated are not well understood. Here, we demonstrate that DRAK2 serves as a TGF-β1-inducible antagonist of TGF-β signaling. TGF-β1 stimulation rapidly induces DRAK2 expression and enhances endogenous interaction of the type I TGF-β receptor with DRAK2, thereby blocking R-Smads recruitment. Depletion of DRAK2 expression markedly augmented the intensity and the extent of TGF-β1 responses. Furthermore, a high level of DRAK2 expression was observed in basal-like and HER2-enriched breast tumors and cell lines, and depletion of DRAK2 expression suppressed the tumorigenic ability of breast cancer cells. Thus, these studies define a function for DRAK2 as an intrinsic intracellular antagonist participating in the negative feedback loop to control TGF-β1 responses, and aberrant expression of DRAK2 increases tumorigenic potential, in part, through the inhibition of TGF-β1 tumor suppressor activity.
Insights
Transforming growth factor-beta 1 (TGF-β1) signaling is regulated by DRAK2, a novel antagonist. Aberrant DRAK2 expression in breast cancer promotes tumorigenesis by inhibiting TGF-β1
Area of Science:
- Cellular Biology
- Molecular Biology
- Cancer Research
Background:
- Transforming growth factor-beta 1 (TGF-β1) is a key cytokine regulating numerous biological processes.
- The termination mechanisms of intracellular TGF-β1 signaling remain incompletely understood.
- Understanding these mechanisms is crucial for deciphering cellular regulation and disease pathogenesis.
Purpose of the Study:
- To identify novel regulators of TGF-β1 signaling termination.
- To investigate the role of DRAK2 in TGF-β1 pathway regulation.
- To explore the implications of DRAK2 in breast cancer development and progression.
Main Methods:
- Investigated TGF-β1-induced gene expression changes.
- Utilized co-immunoprecipitation to study protein interactions.
- Employed siRNA to deplete DRAK2 expression in cell lines.
- Assessed the impact of DRAK2 on TGF-β1 signaling and breast cancer cell tumorigenicity.
Main Results:
- TGF-β1 stimulation rapidly upregulates DRAK2 expression.
- DRAK2 interacts with the TGF-β type I receptor, inhibiting R-Smad recruitment.
- DRAK2 depletion potentiates TGF-β1 signaling.
- Elevated DRAK2 expression correlates with basal-like and HER2-enriched breast tumors.
- DRAK2 depletion reduces breast cancer cell tumorigenic potential.
Conclusions:
- DRAK2 functions as an intrinsic intracellular antagonist in the TGF-β1 signaling negative feedback loop.
- Aberrant DRAK2 expression contributes to tumorigenesis by potentially inhibiting TGF-β1's tumor suppressor functions.
- DRAK2 represents a potential therapeutic target in specific breast cancer subtypes.
Related Concept Videos
TGF - β Signaling Pathway
The JAK-STAT Signaling Pathway
Cell Signaling Feedback Loops
Negative feedback loops
Most signaling systems have negative feedback loops that can perform different functions such as output limiter, and adaptation.
Output limiter
Upon receiving an input signal, the cellular response rapidly increases until a threshold is reached. Beyond this threshold, a negative feedback loop...
Amplifying Signals via Enzymatic Cascade
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...

